Q3 2024 EPS Estimates for Tectonic Therapeutic (NASDAQ:TECX) Decreased by Analyst

Tectonic Therapeutic (NASDAQ:TECX) – Equities research analysts at Leerink Partnrs decreased their Q3 2024 earnings estimates for Tectonic Therapeutic in a research note issued on Thursday, August 15th. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn ($0.70) per share for the quarter, down from their previous forecast of ($0.50). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Tectonic Therapeutic’s current full-year earnings is ($4.24) per share. Leerink Partnrs also issued estimates for Tectonic Therapeutic’s Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($3.33) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.56) EPS, FY2026 earnings at ($2.58) EPS, FY2027 earnings at ($3.74) EPS and FY2028 earnings at ($3.90) EPS.

Several other research analysts have also recently weighed in on the company. SVB Leerink started coverage on Tectonic Therapeutic in a research report on Wednesday, July 24th. They set an “outperform” rating and a $49.00 price objective on the stock. Piper Sandler began coverage on shares of Tectonic Therapeutic in a research report on Wednesday, June 26th. They set an “overweight” rating and a $76.00 price target on the stock. Finally, TD Cowen initiated coverage on shares of Tectonic Therapeutic in a report on Monday, June 24th. They issued a “buy” rating for the company.

Tectonic Therapeutic Price Performance

Shares of TECX stock opened at $16.69 on Monday. Tectonic Therapeutic has a 12-month low of $12.12 and a 12-month high of $19.80. The firm has a market capitalization of $749.28 million, a P/E ratio of 24.19 and a beta of 2.63. The stock’s 50 day moving average is $16.59.

Institutional Trading of Tectonic Therapeutic

A number of institutional investors have recently modified their holdings of TECX. Affinity Asset Advisors LLC acquired a new position in Tectonic Therapeutic in the second quarter valued at about $961,000. Renaissance Technologies LLC bought a new position in Tectonic Therapeutic in the second quarter valued at approximately $1,466,000. Acadian Asset Management LLC acquired a new position in Tectonic Therapeutic during the second quarter valued at approximately $1,804,000. Atlas Venture Life Science Advisors LLC bought a new stake in Tectonic Therapeutic during the second quarter worth $6,233,000. Finally, Farallon Capital Management LLC acquired a new stake in shares of Tectonic Therapeutic in the 2nd quarter valued at $7,099,000. 62.63% of the stock is currently owned by institutional investors.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.